Psilocybin in Adults With and Without Autism Spectrum Disorder

Autism Spectrum Disorder Clinical Trial

— PSILAUT  

Official title:

Modulation of Serotonin Pathways Using Psilocybin in Adults With and Without Autism Spectrum Disorder (ASD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05651126
• Other study ID #: IRAS: 292281; REC: 21/LO/0795
• Status: Recruiting
• Phase: N/A
• Start date: December 12, 2022
• Est. completion date: September 2025

Study information

• Verified date: March 2024
• Source: King's College London
• Contact: Grainne McAlonan
• Phone: 00442078480002
• Email: mrs[@]kcl.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will test the hypothesis that brain systems are differentially regulated by serotonin in individuals with and without Autism Spectrum Disorder.

Description:

To do this, the brain response to two single acute doses of partial serotonin (5HT)1A/2A receptor agonist psilocybin (COMP360) relative to a single dose of placebo (baseline serotonin activity) will be compared in healthy autistic and non-autistic adults. Brain function will be assessed using a range of MRI (fMRI and MRS), EEG and sensory tasks. Unimodal and multimodal analyses will be conducted. Please note that this study uses psilocybin as a probe of the serotonin system in a Case-Control science study and, following Scope protocol review, the U.K. MHRA confirmed that it is not a 'Clinical Trial of an Investigational Medicinal Product' (IMP) as defined by the EU Directive 2001/20/EC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: September 2025
• Est. primary completion date: September 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

For all participants:

• Calendar age above 18 years
• Working knowledge of English
• Able to give informed consent
• Not pregnant or breastfeeding
• Individuals should be in good physical health, prescription medication free during the 2-week period preceding a study visit. However, occasional use of over-the-counter medication (e.g. painkillers) on an as needed basis (and not on the day of study visit) may be permitted. In addition, regular prescription medication (use of a stable dose over the two months preceding participation) with a drug that does not affect 5HT directly may be permitted. Also permitted is topical medication without systemic exposure

For individuals with ASD:

• Diagnosis of ASD by recognised clinical service supported by the Autism Diagnostic Interview-Revised (ADI-R) if a relative is available. Current symptom level assessed using the Autism Diagnostic Observation Schedule (ADOS-2) Exclusion Criteria:

For all participants:

• History of allergy/idiosyncrasy to psilocybin or chemically related compounds or excipients which may be employed in the study or to any other drug used in the past
• Clinically relevant history or presence of any medical disorder, potentially interfering with this study
• Clinically relevant abnormality at screening as judged by the investigator
• History of or current abuse of drugs (including prescription medication) or alcohol or solvents
• Participation in a research study involving a pharmacological probe or drug trial within last month
• Subjects with current epilepsy, seizures or episodes of unexplained and unprovoked loss of consciousness
• Anyone with a history or examination which indicates laboratory testing is needed will be excluded from the study
• Intelligence Quotient below 70
• Currently taking prescription medications of propranolol or pindolol
• Individuals with major mental illness
• Individuals who have a current or past history of meeting diagnostic criteria for schizophrenia or other psychotic disorders or bipolar I or II disorder

Reproductive safety:

• Pregnancy or breastfeeding (is a routine exclusion for research MRI scanning)
• Female study participants must be willing to use one form of highly effective non-hormonal contraception for one week after study drug administration. This would include a vasectomised partner (sole partner), tubal occlusion, intrauterine system [IUS]/hormonal coil or copper containing intrauterine device or copper containing IUD, or true abstinence (when this is in line with the preferred and usual lifestyle of the subject). Women should have been stable on their chosen method of birth control for a minimum of 2 months before entering the study. Participants must agree to undergo a pregnancy test prior to each administration of study drug For individuals with ASD: ASD caused by a known genetic syndrome, e.g. Fragile X, 22q11 deletion syndrome. Currently treated for epilepsy

Related Conditions & MeSH terms

• Autism Spectrum Disorder
• Autistic Disorder
• Child Development Disorders, Pervasive

Intervention

Drug:
• Psilocybin 5 mg
Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
• Psilocybin 2 mg
Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
• Placebo
Inactive placebo

Locations

Country	Name	City	State
United Kingdom	King's College London	London

Sponsors (2)

Lead Sponsor	Collaborator
King's College London	University of Cambridge

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory: Subjective effects intensity	5-Dimensional altered states of consciousness (5D-ASC) used for Case-control comparison of subjective effects intensity at placebo and when serotonin system activated with psilocybin	Data collected on up to 3 visit days per participant.
Primary	Brain activation and connectivity response to serotonergic stimulation as assessed by functional magnetic resonance imaging.	Comparing whole brain blood-oxygen-level-dependent (BOLD) activation (institutional units) during the resting state in cases and controls when the serotonin system is activated by a single oral dose of psilocybin (COMP360) versus the placebo condition.	Data collected on up to 3 visit days per participant.
Primary	Brain electrophysiological activity task-free electroencephalography (EEG)	Case-control comparison of task-free EEG by time-frequency analysis during placebo and when serotonin system is activated with psilocybin.	Data collected on up to 3 visit days per participant.
Primary	Brain electrophysiological activity electroencephalography (EEG) during visual stimulation	Case-control comparison of EEG Evoked Potentials in response to visual stimulation during placebo and when serotonin system is activated with psilocybin.	Data collected on up to 3 visit days per participant.
Primary	Brain electrophysiological activity electroencephalography (EEG) during auditory stimulation	Case-control comparison of EEG Event Related Potentials in response to auditory tones during placebo and when serotonin system is activated with psilocybin.	Data collected on up to 3 visit days per participant.
Secondary	Brain excitation and inhibition response to serotonergic stimulation as assessed by magnetic resonance spectroscopy.	Quantification and case-control comparison of brain metabolites relevant to regulation of excitation and inhibition (focus on Glx, GABA, GSH) using proton magnetic resonance spectroscopy when serotonin system is 'at rest' (placebo) and when activated by psilocybin.	Data collected on up to 3 visit days per participant.